Q2-2012 Revenue Conference call
August 1st, 2012

OneKey

cegedim
This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the ‘Autorité des Marchés Financiers’.
Cegeonim [Sej’ eh deem]

€911m
2011 Revenue

8,200
2011 Headcount

65%
Recurring business

€330m
Market Capitalization as of July 31, 2012

Makes healthcare business run simply and more efficiently
Business stabilizing following the sharp decline in mid 2011 (H1 2012 is on a par with H2 2011)

Satisfactory Q1. Q2 was hit by weaker economic conditions in many developed countries, particularly from June onwards

Fine performance from “healthcare professionals’ software” and “third party payment”

Ramp-up of “CRM and Strategic Data” in China

Extension of the Performance Improvement Program

Cegedim focus on innovation and deleveraging
Well-balanced and diversified revenue mix

Q2 2012 Revenue breakdown

<table>
<thead>
<tr>
<th>Activity</th>
<th>Geography</th>
<th>Currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>A CRM &amp; Strategic Data 52%</td>
<td>A France 55%</td>
<td>A EUR 65%</td>
</tr>
<tr>
<td>B Healthcare Professionals 32%</td>
<td>B EMEA ex. France 26%</td>
<td>B USD 12%</td>
</tr>
<tr>
<td>C Insurance &amp; Services 16%</td>
<td>C America 14%</td>
<td>C GBP 9%</td>
</tr>
<tr>
<td>D APAC 6%</td>
<td>D RoW 14%</td>
<td>D</td>
</tr>
</tbody>
</table>
The situation in Southern European countries (11% of sector revenue), remains difficult.

Emerging countries are still rapidly expanding with a notable ramp-up in China.

Positive impact starting in H2 2012 of contracts signed in 2011.

Cegedim continues to deliver a steady stream of innovation (Compliance, CRM on iPad, Multi-channel,…).
Renewed growth in Cegelease’s activity continue in Q2

RNP: Difficult advertising market.

Fine performance from Cegedim Healthcare Software, driven principally by the computerization of Pharmacists in the UK and Doctor in France.

Cegedim should continue to benefit from the development of performance-based pay for physicians around the world.
Insurance & Services

Comprehensive Solutions for Payers

IT for Healthcare Insurers

Flows and Electronic Payments

Services

Q2 2012 Performance

<table>
<thead>
<tr>
<th>Q2 2011</th>
<th>€36.3m</th>
<th>+0.6%</th>
<th>+0.0%</th>
<th>€36.5m</th>
</tr>
</thead>
</table>

Q2 2012 Highlights

- Personal insurance companies' hesitancy in the second quarter due to the French election and the weaker economic conditions.
- Positive impact from favorable developments in online third-party payer management services
  - Future growth will be fuelled by expanding these offerings
- Strong growth in payroll and HR outsourcing solutions
Cegedim sold its Pharmapost subsidiary on April 30, 2012 to the Chesapeake group

- One of France’s leading printers of drug information sheets
- Synergies with the Group were limited
- 2011 contribution to Group consolidated revenues: €5.9 million
- 2011 contribution to consolidated EBITDA: close to zero

*Under the terms of the agreement between the two parties, all other details regarding the transaction are confidential*
Acquisition of ASP Line in France.

- France's fourth-largest publisher of pharmacist software
- Serving more than 1,300 pharmacies present around the country
- Strengthening Cegedim's leadership position
- Software rental business model
- Annual revenues: around €9 million
- Part of the consolidation scope of Cegedim Group from July 1, 2012 onward

Under the terms of the agreement between the two parties, all other details regarding the transaction are confidential
Outlook$^{(1)}$

- Economic environment will remain tough in H2 2012
- The Performance Improvement Program is extended into the H2 2012
- No plan to make further acquisitions by the end of the year

2012 Outlook$^{(1)}$

- The Group is now expecting a decline in H1 EBITDA compared to the same period of 2011
- The target for H2 2012 is to achieve a revenue and EBITDA level on a par with that of H2 2011

$^{(1)}$ These projections are as publicly disclosed on August 2012. The fact that Cegedim include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date.
A Resilient Core Business and a Solid Financial Profile

→ Steady Business Profile
  - Recurring revenues relying mostly on a subscription based model (~65% of revenue)
  - Critical size with strong market share in all business segment
  - Secular trend will favor Cegedim (Healthcare reform, Transparency, Pay for performance, …)

→ Strong Financial Profile
  - Revenue growth vs. fixed costs creates margin opportunity
  - Strong cash flow generation provides liquidity for deleveraging
  - Robust liquidity position

→ Conservative Financing Policy
  - Performance Improvement Program
  - Family-owned company with experienced team
  - Active debt management (credit facility refinancing, dividend cut in 2012, …)
  - Virtually no acquisition in 2011 and 2012
Half-year revenue evolution

<table>
<thead>
<tr>
<th>Cegedim</th>
<th>CRM &amp; Strategic Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>€458.6m</td>
<td>€249.2m</td>
</tr>
<tr>
<td>-2.8%</td>
<td>-6.7%</td>
</tr>
<tr>
<td>+1.7%</td>
<td>+2.3%</td>
</tr>
<tr>
<td>€452.5m</td>
<td>€237.1m</td>
</tr>
<tr>
<td>-0.2%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>-1.3%</td>
<td>-4.9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Healthcare professionals</th>
<th>Insurance &amp; Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>€140.2m</td>
<td>€69.1m</td>
</tr>
<tr>
<td>+0.3%</td>
<td>+4.5%</td>
</tr>
<tr>
<td>+0.3%</td>
<td>+0.0%</td>
</tr>
<tr>
<td>+1.5%</td>
<td>+0.0%</td>
</tr>
<tr>
<td>€143.1m</td>
<td>€72.3m</td>
</tr>
<tr>
<td>+2.1%</td>
<td>+4.5%</td>
</tr>
</tbody>
</table>

Organic | Structure | Currency

This document should not be distributed without Cegedim authorization – Copyright 2012
Strong and stable shareholder base

Shareholder base as of end of June 2012

Board of directors

- Jean-Claude Labrune - Chairman of the board
- Laurent Labrune
- Aude Labrune
- Jean-Louis Mery
- Philippe Tcheng - Representative of GERS, GIE
- Pierre Marucchi - Representative of FOB
- Jacques-Henri David - Appointed by the FSI
- Nicolas Manardo - Representative of the FSI
- Anthony Roberts - Representative of Alliance Healthcare France
- Jean-Pierre Cassan - Independent board member in the sense of the AFEP-MEDEF code

Corporate governance

- Compliance with the recommendation of the AFEP-MEDEF code
- Audit, Strategy, Nomination and Compensation committees
Analyst coverage
(as of August 1, 2012)

**Bond (public research)**
- *Exane*: Benjamin Sabahi
- *Imperial Capital*: Diego Affò
- *Société Générale*: Juliano Hiroshi Torii

**Equity**
- *CA Cheuvreux*: Michael Beucher
- *CM-CIC securities*: Jean-Pascal Brivady
- *Gilbert Dupont*: Mickael Chane-Du
- *Natixis Securities*: Thomas Le Quang
- *Oddo & Cie*
- *Société Générale*: Patrick Jousseaume
2012 Finance agenda

January 12
Investors’ Day

February 2
2011 Revenue

April 2
2011 Annual results

April 3
SFAF Meeting

May 3
2012 Q1 revenue

August 1st
2012 Q2 revenue

September 19
2012 Half-year results

September 20
SFAF Meeting

November 8
2012 Q3 revenue
We welcome your questions and comments

Jan Eryk UMIASTOWSKI
Chief Investment Officer
Head of Investor Relations

janeryk.umiaestowski@cegedim.com
www.cegedim.com/finance

TEL: +33 (0) 1 49 09 33 36